Companion Diagnostics Market by Technology, Indication, and End User - Global Forecast to 2022

  • ID: 4367906
  • Report
  • Region: Global
  • 172 Pages
  • Markets and Markets
1 of 6
The Global Companion Diagnostics Market is Projected to Reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Almac Group
  • Biomérieux SA
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Novartis AG
  • MORE

“Global companion diagnostics market projected to grow at CAGR of 20.1%”

The global companion diagnostics market is projected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. However, uncertain reimbursement scenarios in different countries such as the U.S., the U.K., Japan, and Australia are expected to limit market growth.

“The assay kits & reagents segment is expected to grow at the fastest CAGR"

On the basis of product and service, the companion diagnostics market is segmented into assay kits & reagents, and software & services. The assay kits & reagents segment accounted for the largest share in 2016 and is expected to register the highest CAGR during the forecast period. The large share can be attributed to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH.

“The oncology segment to dominate the global companion diagnostics market with largest share and fastest CAGR”

Based on indication, the companion diagnostics market is further categorized into oncology, infectious diseases, neurology, and other indications (including cardiovascular, inflammatory, and inherited diseases). In 2016, the oncology segment accounted for the largest share and is also the fastest growing segment of the market; this is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also broadened the role of companion diagnostics in this field.

”The pharmaceutical and biopharmaceutical companies segment is expected to grow at the fastest CAGR”

On the basis of end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2016. This end-user segment is also expected to register the highest CAGR during the forecast period. The large share and growth of this market can be attributed to increasing and significant application of companion diagnostics in the drug development process.

“Asia-Pacific to witness the fastest growth during the forecast period (2017-2022)”

North America held the largest share of the global companion diagnostics market in 2016, while Asia-Pacific is expected to witness the highest growth during 2017 to 2022. Growing need for tailored therapeutics by the elderly population, increasing number of hospitals and diagnostic laboratories, and growing prevalence of life-threatening diseases are driving the growth of the companion diagnostics market in the Asia-Pacific region.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-45%, Tier 2-34%, and Tier 3-21%
  • By Designation - C-level-14%, Director Level-10%, and Others-76%
  • By Region - North America-40%, Europe-32%, Asia-Pacific-20%, and RoW-8%

Some of the major market players in the companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), and QIAGEN N.V. (Netherlands) dominated the global companion diagnostics market. Some of the other players competing in this market are Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Danaher Corporation (U.S.), Almac Group (U.S.), and Sysmex Corporation (Japan).

Research Coverage:

The report analyzes the companion diagnostics market and aims at estimating market size and future growth potential of this market based on various segments such as product and service, type of medical device, application, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product and service portfolios offered by the top players in the global companion diagnostics market. The report analyzes the global companion diagnostics market by product and service, technology, indication, end user, and region
  • Product/Service Enhancement/Innovation: Detailed insights on upcoming trends and new product/service launches in the global companion diagnostics market
  • Market Development: Comprehensive information on the lucrative emerging markets by product and service, type of medical device, application, and region
  • Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global companion diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, services, and capabilities of leading players in the global market
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories, Inc.
  • Almac Group
  • Biomérieux SA
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Novartis AG
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered in the Report
1.3 Currency
1.4 Limitations
1.5 Stakeholders

2 Research Methodology
2.1 Market Size Estimation
2.2 Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Global Companion Diagnostics Market Overview
4.2 Global Market, By Indication
4.3 Global Market, By Product & Services
4.4 Global Market, By Technology

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Improvements in Regulatory Guidelines
5.2.1.2 Growing Need for Targeted Therapies
5.2.1.3 Rising Cancer Incidence Worldwide
5.2.1.4 Increasing Collaborations and Partnerships for Companion Diagnostics Test Development
5.2.2 Restraints
5.2.2.1 Uncertain Reimbursement Scenarios in Different Regions
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Next-Generation Sequencing
5.2.3.2 Increasing Number of Clinical Trials to Boost the Adoption of Companion Diagnostics
5.2.3.3 Emerging Applications of Companion Diagnostics in Other Cancer Indications, Neurological Disorders, Infectious Diseases, and Cardiovascular Diseases
5.2.4 Challenge
5.2.4.1 Intellectual Property Rights Protection Issues

6 Companion Diagnostics Market, By Product & Service
6.1 Introduction
6.2 Assay Kits and Reagents
6.3 Software & Services

7 Companion Diagnostics Market, By Technology
7.1 Introduction
7.2 Polymerase Chain Reaction
7.3 Immunohistochemistry
7.4 In Situ Hybridization
7.5 Next-Generation Sequencing
7.6 Other Technologies

8 Companion Diagnostics Market, By Indication
8.1 Introduction
8.2 Oncology
8.2.1 Breast Cancer
8.2.2 Lung Cancer
8.2.3 Colorectal Cancer
8.2.4 Melanoma
8.2.5 Gastric Cancer
8.2.6 Other Cancers
8.3 Neurology
8.4 Infectious Diseases
8.5 Other Indications

9 Companion Diagnostics Market, By End User
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Reference Laboratories
9.4 Other End Users

10 Companion Diagnostics Market, By Region
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Rest of Europe
10.4 Asia-Pacific
10.5 Rest of the World

11 Competitive Landscape
11.1 Introduction
11.2 Market Ranking Analysis
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Competitive Benchmarking
11.4.1 Strength of Product Portfolio (For 25 Players)
11.4.2 Business Strategy Excellence (For 25 Players)

*Top 25 Companies Analyzed for This Studies are - Abbott Laboratories, Inc., Agilent Technologies, Inc., Biomérieux SA, Danaher Corporation, Illumina Inc., Myriad Genetics, Inc., Qiagen N.V., Roche Diagnostics, Thermo Fisher Scientific, Inc., Arup Laboratories Inc., Sysmex Corporation, Hologic, Inc., Novartis Ag, Almac Group, Abnova Corporation Invivoscribe Technologies, Inc., Foundation Medicine, Inc., Biogenex Laboratories, Inc., Laboratory Corporation of America Holdings, Medical & Biological Laboratories Co., Ltd, Clarity Pharmaceuticals, Researchdx, Inc., Neogenomics Laboratories, Inc., Janssen Diagnostics, Siemens Healthcare Diagnostics Inc.

12 Company Profiles
(Overview, Business Overview, Business Strategy Excellence, Recent Developments)*
12.1 F. Hoffmann-La Roche AG
12.2 Agilent Technologies, Inc.
12.3 Qiagen N.V.
12.4 Thermo Fisher Scientific Inc.
12.5 Abbott Laboratories, Inc.
12.6 Biomérieux SA
12.7 Danaher Corporation
12.8 Illumina, Inc.
12.9 Myriad Genetics, Inc.
12.10 Arup Laboratories Inc.
12.11 Sysmex Corporation
12.12 Hologic Inc.
12.13 Novartis AG
12.14 Almac Group
12.15 Abnova Corporation

13 Appendix
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details

List of Tables
Table 1 Companion Diagnostics Reimbursement Scenario Worldwide
Table 2 Partnerships and Collaborations for Developing Ngs-Based Companion Diagnostic Tests
Table 3 List of Clinical Trials for Companion Diagnostics
Table 4 Global Companion Diagnostics Market, By Product and Service, 2015-2022 (USD Million)
Table 5 Market for Assays & Reagents, By Region, 2015-2022 (USD Million)
Table 6 North America: Market for Assays & Reagents, By Country, 2015-2022 (USD Million)
Table 7 Europe: Market for Assays & Reagents, By Country, 2015-2022 (USD Million)
Table 8 Market for Software & Services, By Region, 2015-2022 (USD Million)
Table 9 North America: Market for Software & Services, By Country, 2015-2022 (USD Million)
Table 10 Europe: Market for Software & Services, By Country, 2015-2022 (USD Million)
Table 11 Global Companion Diagnostics Market, By Technology, 2015-2022 (USD Million)
Table 12 Comparison of Tissue Sequencing Platforms for Detection of Ras/Braf Mutation
Table 13 Companion Diagnostics Market for PCR, By Region, 2015-2022 (USD Million)
Table 14 North America: Market for PCR, By Country, 2015-2022 (USD Million)
Table 15 Europe: Market for PCR, By Country, 2015-2022 (USD Million)
Table 16 Market for Ihc, By Region, 2015-2022 (USD Million)
Table 17 North America: Market for Ihc, By Country, 2015-2022 (USD Million)
Table 18 Europe: Market for Ihc, By Country, 2015-2022 (USD Million)
Table 19 Companion Diagnostics Market for Ish, By Region, 2015-2022 (USD Million)
Table 20 North America: Market for Ish, By Country, 2015-2022 (USD Million)
Table 21 Europe: Market for Ish, By Country, 2015-2022 (USD Million)
Table 22 Companion Diagnostics Market for Ngs, By Region, 2015-2022 (USD Million)
Table 23 North America: Market for Ngs, By Country, 2015-2022 (USD Million)
Table 24 Europe: Market for Ngs, By Country, 2015-2022 (USD Million)
Table 25 Market for Other Technologies, By Region, 2015-2022 (USD Million)
Table 26 North America: Market for Other Technologies, By Country, 2015-2022 (USD Million)
Table 27 Europe: Market for Other Technologies, By Country, 2015-2022 (USD Million)
Table 28 Global Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 29 Market for Oncology, By Type, 2015-2022 (USD Million)
Table 30 Market for Oncology, By Region, 2015-2022 (USD Million)
Table 31 North America: Market for Oncology, By Country, 2015-2022 (USD Million)
Table 32 Europe: Market for Oncology, By Country, 2015-2022 (USD Million)
Table 33 Market for Neurological Disorders, By Region, 2015-2022 (USD Million)
Table 34 North America: Companion Diagnostics Market for Neurological Disorders, By Country, 2015-2022 (USD Million)
Table 35 Europe: Companion Diagnostics Market for Neurological Disorders, By Country, 2015-2022 (USD Million)
Table 36 Companion Diagnostics Market for Infectious Diseases, By Region, 2015-2022 (USD Million)
Table 37 North America: Market for Infectious Diseases, By Country, 2015-2022 (USD Million)
Table 38 Europe: Market for Infectious Diseases, By Country, 2015-2022 (USD Million)
Table 39 Market for Other Indications, By Region, 2015-2022 (USD Million)
Table 40 North America: Market for Other Indications, By Country, 2015-2022 (USD Million)
Table 41 Europe: Market for Other Indications, By Country, 2015-2022 (USD Million)
Table 42 Global Market, By End User, 2015-2022 (USD Million)
Table 43 Companion Diagnostics Market for Pharmaceutical and Biopharmaceutical Companies, By Region, 2015-2022 (USD Million)
Table 44 North America: Companion Diagnostics Market for Pharmaceutical and Biopharmaceutical Companies, By Country, 2015-2022 (USD Million)
Table 45 Europe: Market for Pharmaceutical and Biopharmaceutical Companies, By Country, 2015-2022 (USD Million)
Table 46 Companion Diagnostics Market for Reference Laboratories, By Region, 2015-2022 (USD Million)
Table 47 North America: Companion Diagnostics Market for Reference Laboratories, By Country, 2015-2022 (USD Million)
Table 48 Europe: Market for Reference Laboratories, By Country, 2015-2022 (USD Million)
Table 49 Market for Other End Users, By Region, 2015-2022 (USD Million)
Table 50 North America: Market for Other End Users, By Country, 2015-2022 (USD Million)
Table 51 Europe: Market for Other End Users, By Country, 2015-2022 (USD Million)
Table 52 Companion Diagnostics Market, By Region, 2015-2022 (USD Million)
Table 53 North America: Companion Diagnostics Market, By Country, 2015-2022 (USD Million)
Table 54 North America: Market, By Product & Service, 2015-2022 (USD Million)
Table 55 North America: Companion Diagnostics Market, By Technology, 2015-2022 (USD Million)
Table 56 North America: Market, By Indication, 2015-2022 (USD Million)
Table 57 North America: Companion Diagnostics Market for Oncology, By Type, 2015-2022 (USD Million)
Table 58 North America: Market, By End User, 2015-2022 (USD Million)
Table 59 U.S.: Companion Diagnostics Market, By Product & Service, 2015-2022 (USD Million)
Table 60 U.S.: Market, By Technology, 2015-2022 (USD Million)
Table 61 U.S.: Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 62 U.S.: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 63 U.S.: Companion Diagnostics Market, By End User, 2015-2022 (USD Million)
Table 64 Canada: Companion Diagnostics Market, By Product & Service, 2015-2022 (USD Million)
Table 65 Canada: Market, By Technology, 2015-2022 (USD Million)
Table 66 Canada: Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 67 Canada: Market Size for Oncology, By Type, 2015-2022 (USD Million)
Table 68 Canada: Companion Diagnostics Market, By End User, 2015-2022 (USD Million)
Table 69 Europe: Companion Diagnostics Market, By Country, 2015-2022 (USD Million)
Table 70 Europe: Market, By Product & Service, 2015-2022 (USD Million)
Table 71 Europe: Companion Diagnostics Market, By Technology, 2015-2022 (USD Million)
Table 72 Europe: Market, By Indication, 2015-2022 (USD Million)
Table 73 Europe: Companion Diagnostics Market for Oncology, By Type, 2015-2022 (USD Million)
Table 74 Europe: Market, By End User, 2015-2022 (USD Million)
Table 75 Germany: Companion Diagnostics Market, By Product & Service, 2015-2022 (USD Million)
Table 76 Germany: Market, By Technology, 2015-2022 (USD Million)
Table 77 Germany: Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 78 Germany: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 79 Germany: Companion Diagnostics Market, By End User, 2015-2022 (USD Million)
Table 80 France: Companion Diagnostics Market, By Product & Service, 2015-2022 (USD Million)
Table 81 France: Market, By Technology, 2015-2022 (USD Million)
Table 82 France: Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 83 France: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 84 France: Market, By End User, 2015-2022 (USD Million)
Table 85 U.K.: Companion Diagnostics Market, By Product & Service, 2015-2022 (USD Million)
Table 86 U.K.: Market, By Technology, 2015-2022 (USD Million)
Table 87 U.K.: Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 88 U.K.: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 89 U.K.: Companion Diagnostics Market, By End User, 2015-2022 (USD Million)
Table 90 RoE: Companion Diagnostics Market, By Product & Service, 2015-2022 (USD Million)
Table 91 RoE: Market, By Technology, 2015-2022 (USD Million)
Table 92 RoE: Companion Diagnostics Market, By Indication, 2015-2022 (USD Million)
Table 93 RoE: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 94 RoE: Companion Diagnostics Market, By End User, 2015-2022 (USD Million)
Table 95 APAC: Market, By Product & Service, 2015-2022 (USD Million)
Table 96 APAC: Market, By Technology, 2015-2022 (USD Million)
Table 97 APAC: Market, By Indication, 2015-2022 (USD Million)
Table 98 APAC: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 99 APAC: Market, By End User, 2015-2022 (USD Million)
Table 100 RoW: Market, By Product & Service, 2015-2022 (USD Million)
Table 101 RoW: Market, By Technology, 2015-2022 (USD Million)
Table 102 RoW: Market, By Indication, 2015-2022 (USD Million)
Table 103 RoW: Market for Oncology, By Type, 2015-2022 (USD Million)
Table 104 RoW: Market, By End User, 2015-2022 (USD Million)
Table 105 Rank of Companies in the Companion Diagnostics Market, 2016

List of Figures
Figure 1 Research Design
Figure 2 Bottom Up Approach
Figure 3 Top Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Global Market, By Technology, 2017 vs 2022
Figure 7 Global Market, By Indication, 2017 vs 2022
Figure 8 Global Market, By Products & Services, 2017 vs 2022
Figure 9 Global Market, By End User, 2017 vs 2022
Figure 10 Geographical Snapshot of the Companion Diagnostics Market
Figure 11 Increasing Demand for Targeted Therapy is Boosting the Companion Diagnostics Market
Figure 12 Oncology Segment is Estimated to Account for the Largest Market Share in 2017
Figure 13 Assays & Reagents Segment is Estimated to Account for the Largest Market Share in 2017
Figure 14 Polymerase Chain Reaction is Estimated to Account for the Largest Market Share in 2017
Figure 15 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 16 Increasing Number of New Cancer Cases Worldwide, 2012 vs 2015 vs 2020
Figure 17 Assay Kits and Reagents Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 18 PCR Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 19 Oncology Segment to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 20 Pharmaceutical and Biopharmaceutical Companies Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 21 Geographic Snapshot: Asia-Pacific Market to Register Highest Growth During the Forecast Period
Figure 22 North American Companion Diagnostics Market Snapshot
Figure 23 European Companion Diagnostics Market Snapshot
Figure 24 Asia-Pacific Companion Diagnostics Market Snapshot
Figure 25 Competitive Leadership Mapping, 2017
Figure 26 F. Hoffmann-La Roche AG: Company Snapshot (2016)
Figure 27 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 28 Qiagen N.V.: Company Snapshot (2016)
Figure 29 Thermo Fisher Scientific Inc.: Company Snapshot (2016)
Figure 30 Abbott Laboratories, Inc.: Company Snapshot (2016)
Figure 31 Biomérieux SA: Company Snapshot (2016)
Figure 32 Danaher Corporation: Company Snapshot (2016)
Figure 33 Illumina, Inc.: Company Snapshot (2016)
Figure 34 Myriad Genetics, Inc.: Company Snapshot (2016)
Figure 35 Sysmex Corporation: Company Snapshot (2016)
Figure 36 Hologic, Inc.: Company Snapshot (2016)
Figure 37 Novartis AG: Company Snapshot (2016)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Abbott Laboratories, Inc.
  • Abnova Corporation
  • Agilent Technologies, Inc.
  • Almac Group
  • Arup Laboratories Inc.
  • Biomérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Qiagen N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll